Table 1.
Patients' characteristics
| Patients with bevacizumab-related HTN (N=41) | Patients without bevacizumab-related HTN (N=38) | |
|---|---|---|
| Median age (years) | 60.2 (32.7–77.3) | 60.4 (31.6–78.8) |
| Male:female | 28 (68.3%):13 (31.7%) | 25 (65.8%):13 (34.2%) |
| Primary tumour location | ||
| Colon | 26 (63.4%) | 24 (63.2%) |
| Rectum | 15 (36.6%) | 14 (36.8%) |
| Metastases location | ||
| Liver | 27 (65.9%) | 31 (81.6%) |
| Lung | 11 (26.8%) | 8 (21.1%) |
| Liver+Lung | 6 (14.6%) | 5 (13.2%) |
| Peritoneal, lymph nodes, bone, ovary and penis | 8 (19.5%) | 5 (13.2%) |
| Primary tumour surgery | ||
| Colon | 23 (56.1%) | 14 (36.8%) |
| Rectum | 8 (19.5%) | 4 (10.5%) |
| Previous chemotherapy (CT) | ||
| Stage II | 1 (2.4%) | 2 (5.2%) |
| Stage III | 11 (26.8%) | 9 (23.7%) |
| Chemotherapy (CT) associated with bevacizumab frontline | ||
| FOLFIRI | 37 (90.2%) | 36 (94.7%) |
| FOLFOX | 4 (9.8%) | 2 (5.3%) |
| RAS status | 36 (87.8%) | 34 (89.5%) |
| KRAS (wt:mutated) | 22 (61.1%):14 (38.9%) | 19 (55.9%):15 (44.1%) |
| NRAS (wt:mutated) | 9 (25%):0 (0%) | 4 (11.8%):0 (0%) |
| Proteinuria (yes:no) | 0 (0%):41 (100%) | 0 (0%):38 (100%) |
| Previous diagnosis of HTN | 15 (36.6%) | 17 (44.7%) |
| Maintained treatment until progression (after initiating antihypertensive treatment) | 38 (100%) | N/A |
| ACE inhibitors | 34 | |
| ARB | 4 | |
| Suspended treatment with bevacizumab | 3 (7.3%) | 1 (2.6%) |
| Thromboembolic event | 2 (66.7%) | 1 (100%) |
| Fistulisation | 1 (33.3%) | 0 (0%) |
| Response rate (%) | 73.2 | 18.4 |
| Disease control (%) | 97.6 | 63.2 |
| Median OS (months) | 33 | 21 |
ARB, angiotensin receptor blockers; HTN, hypertension; N/A, not applicable; OS, overall survival.